Table 2:
In-hospital and short-term outcomes in rheumatic AS patients who underwent SAVR versus TAVR, before and after PS weighting adjustment
| Before adjustment | After adjustment | |||||
|---|---|---|---|---|---|---|
| Outcome | SAVR (N=554) | TAVR (N=605) | P value | SAVR (N=554) | TAVR (N=605) | P value |
| AKI, % | 22.1 | 14.4 | 0.02 | 22.3 | 11.9 | 0.02 |
| Blood transfusion, % | 20.1 | 9.1 | 0.002 | 19.8 | 7.6 | 0.002 |
| Cardiogenic shock, % | 5.6 | <1.7 | 0.04 | 5.7 | 1.5 | 0.047 |
| New onset AF, % | 28.3 | 2.2 | <0.001 | 21.1 | 2.2 | <0.001 |
| New PPM, % | 6.0 | 12.2 | 0.001 | 7.2 | 12.5 | 0.1 |
| Length of hospital stay | 7 (5–10) | 3 (2–7) | <0.001 | 8 (6–12) | 3 (2–6) | <0.001 |
| In-hospital mortality, % | 2.2 | 2.2 | 0.8 | 3.5 | 2.4 | 0.6 |
| 30-day stroke, % | 2.2 | 2.0 | 0.8 | 2.8 | 2.4 | 0.8 |
| 30-day mortality, % | 2.4 | 3.6 | 0.3 | 3.2 | 3.6 | 0.9 |
| One-year mortality | 6.1 | 16.0 | <0.001 | 8.9 | 13.1 | 0.2 |
AF= atrial fibrillation; AKI= acute kidney injury; PPM= permanent pacemaker; SAVR= surgical aortic valve replacement; TAVR= transcatheter aortic valve replacement
Cells with N<11 were suppressed with (--)per CMS policy.